Week in Review: Cannabis & Psychedelics Industry Highlights

LOS ANGELES – Highly Capitalized Network-HCN tracked meaningful steps in operational strengthening, capital readiness, and program performance across the Cannabis and Psychedelics sectors during the past two weeks. The capital markets finally spoke, and they said consolidation.

Two of the largest U.S. Сannabis companies moved simultaneously to restructure their share counts ahead of anticipated listings on major U.S. exchanges. State regulators, meanwhile, were writing new patient access rules. And the science on psychedelics kept marching forward with a peer-reviewed landmark that Washington is unlikely to ignore. Here is what mattered most.

1. U.S. Operators Build Operational Strength & Capital Foundations

Vireo Growth Inc. signed a letter of intent to acquire Bridgewell Agribusiness LLC, securing organic and non-GMO sourcing capabilities for approximately $10.26 million net after debt adjustments. The deal enhances supply chain management for edibles and packaged goods, complementing prior moves like Eaze and Hawthorne acquisitions.

Curaleaf Holdings announced a 1-for-3 reverse stock split to meet requirements for major U.S. exchange listing. Verano Holdings pursued a similar 1-for-5 consolidation. These actions, paired with AYR Wellness transferring operations in three states to Arboretum and Glass House Brands completing warrant redemption, reflect disciplined portfolio management and equity refinement aimed at improved liquidity and institutional appeal.

Village Farms International earned Producer of the Year recognition, while Abstrax gained a spot on Fast Company’s Most Innovative Companies list for advancements in the space.

2. State Programs Deliver Revenue & Access Gains

California Cannabis retailers generated nearly $248 million in combined excise and sales tax revenue in Q1 2026, contributing to programs in childcare, prevention, research, and environmental efforts. Cumulative collections since 2018 surpass $8.1 billion, demonstrating consistent public funding support even with unlicensed market pressures.

Kentucky’s governor expanded medical Cannabis eligibility, broadening patient access. In the UK, heavyweight boxer Derek Chisora introduced the WarOnPain platform to facilitate medical Cannabis options for chronic pain management.

3. Research & Tools Advance Safety, Innovation & Efficiency

A California NORML pilot study determined that licensed Cannabis vape pens emit significantly lower levels of key combustion toxins than pre-roll joints, with benzene and acrolein eliminated entirely in vapes. The data reinforces consumer preferences in a category that continues to capture substantial market share.

FundCanna introduced a free dispensary inventory calculator to support operational management.

On the policy front, Reps. Steven Horsford and Steve Cohen led a bipartisan congressional letter to Treasury Secretary Scott Bessent and IRS Chief Executive Officer Frank Bisignano calling for clear guidance on the tax treatment of state-legal Cannabis businesses.

4. International Regulatory Divergence

Global Cannabis regulation continued its uneven march, with developments that cut in opposite directions depending on the jurisdiction.

Argentina’s lower house of Congress received a comprehensive Cannabis legalization bill, introduced by national deputies, that would establish a regulated framework for adult-use, medical, and industrial Cannabis.

At the other end of the regulatory spectrum, Greece’s medicines regulator ordered an immediate nationwide halt to the retail sale of dried Cannabis flower, pulling a product that had built market traction and placing EU operators doing business through Greek retail channels on uncertain ground.

Nigeria’s National Assembly, meanwhile, is drafting legislation to legalize Cannabis for medical, pharmaceutical, and industrial purposes, marking the most significant regulatory movement the country has seen on this question.

And from Asia, Japan’s National Police Agency data revealed that police investigated a record 6,832 individuals for Cannabis-related offenses, with the sharp rise concentrated among younger demographics – a law enforcement signal that often precedes policy reassessment in markets where prohibition is straining under consumer demand.

5. Psychedelics Reach Clinical Legitimacy

Oregon wrapped its first full year of psilocybin services data collection. The program recorded thousands of clients and sessions in 2025, with individual formats predominant, group sessions rising in share, and average product prices declining amid expanded competition. Safety metrics held firm while some service centers navigated cost challenges. Separate research pointed to psilocybin’s promise in addressing cocaine addiction, expanding the therapeutic evidence base.

HCN Insight

Pull back from the individual headlines and five structural signals emerge from this fortnight, each worth tracking independently, but more significant in combination.

Capital Structure Alignment Is Accelerating

The simultaneous reverse splits across Curaleaf, Verano, and Vireo represent a coordinated industry posture shift. MSO leadership has decided the cost of inaction now exceeds the risk of moving. That is a different calculation than the one these same companies were making twelve months ago. It reflects a read on the federal environment, specifically on the possibility of U.S. exchange listings materializing in the next 12 to 18 months. That is more optimistic than the market currently prices in. If even one major listing closes successfully, it will reprice the sector.

Two For Tango: 280E Relief & Capital Access

The congressional letter to the IRS did not appear in isolation. It landed the same week that three MSOs restructured for exchange listings and in the same news cycle as Kentucky’s executive order expansion. The pattern suggests coordinated advocacy across the legislative, regulatory, and operational levels of the industry – a degree of strategic alignment that has been absent for most of the past three years.

Psychedelics Crossed a Clinical Threshold

The JAMA Network Open psilocybin trial for cocaine use disorder is the evidentiary standard that FDA advisory committees work from. Combined with Oregon’s first full year of operational psilocybin data, the sector now has both clinical evidence and real-world regulatory precedent to point to. The investment community can begin underwriting that without speculating on it.

Consumer Validation Is Broadening

The California NORML vape emissions data, Abstrax’s Fast Company recognition, and the Chisora medical platform in the UK all point toward the same shift: Cannabis & Psychedelics are generating mainstream credibility through channels that have nothing to do with lobbying. Consumer-facing science, mainstream innovation rankings, and athlete health narratives reach audiences that trade press never touches.

Global Divergence

For any operator or investor thinking about international exposure, this week’s spread – Argentina opening, Greece closing, Nigeria drafting, Japan enforcing at record levels – is a useful forcing function. The international opportunity in Cannabis is real, but it is not uniform and it is not stable. The operators who will profit from it are those who treat regulatory intelligence as a core competency, not a quarterly briefing. The GCNC-Whitney Economics report on EU and UK markets is the kind of primary intelligence that belongs in every international deal room.

The week’s bottom line: the industry is not waiting for Washington to rescue it. It is restructuring capital, building clinical evidence, expanding state-level access, and reading global markets on its own timeline. That is a more mature industry than the one that existed three years ago. The data is beginning to reflect it.